All In Biotech

NDA 213218 · Sarfe Pharms

Soaanz

Torsemide · Oral · Loop Diuretic

Last checked: Nov 20, 2026Latest source record: Nov 17, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jun 14, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

44

8 Phase 3, 3 recruiting

FAERS reports

33,936

27,263 serious, 4,525 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 9, 2026.

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 14, 2021 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
3 products under this application
  • SOAANZ · TORSEMIDE 60MG · TABLET, ORAL · Discontinued
  • SOAANZ · TORSEMIDE 40MG · TABLET, ORAL · Prescription
  • SOAANZ · TORSEMIDE 20MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Torsemide" as an intervention, any sponsor and status, largest first.

All 44 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea3,621
  • fatigue2,261
  • diarrhoea2,143
  • nausea2,119
  • dizziness2,004
  • acute kidney injury1,817
  • death1,768
  • general physical health deterioration1,689
  • fall1,676
  • oedema peripheral1,628
  • headache1,597
  • hypotension1,545

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004224
2005282
2006323
2007327
2008410
2009521
2010572
2011821
2012975
2013404
2014550
2015848
20161,256
20171,175
20181,481
20191,745
20201,934
20212,830
20224,327
20233,026
20243,598
20253,685
20262,622

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Soaanz (Torsemide)

2024 spending

$5.2M

Beneficiaries

5,342

12,012 claims

Per beneficiary

$965

$9.27 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,329,075
2023$4,786,854
2024$5,153,740

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 57 on PubMed

Sponsor: Sarfe Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.